Table 2.

Selected enriched pathways in DKD glomeruli.

Pathway	NES	P-value	FDR q-value	Molecules
Cardiac muscle contraction	1.70E + 00	1.95E – 03	2.50E – 01	CACNA1C, TNNT2, ACTC1, MYH6, RYR2, ATP1A3, MYH7, CACNA1D, CACNB3, TPM2, CACNA2D1, CACNA2D4, and MYL2
Dilated cardiomyopathy	1.67E + 00	2.04E – 03	1.86E – 01	CACNA1C, TNNT2, ITGA11, SGCA, ACTC1, MYH6, ADCY3, RYR2, ITGB4, MYH7, ADCY5, CACNA1D, TGFB3, DES, ADCY4, CACNB3, TPM2, CACNA2D1, and CACNA2D4
Tight junction	1.58E + 00	2.06E – 03	1.98E – 01	CLDN23, CLDN22, MYH6, MAGI2, MYH11, TJP3, MYH7, CLDN9, CLDN11, MYH3, PPP2R2C, CLDN6, MYH14, ACTN3, CLDN4, CLDN15, CLDN14, MYL2, PARD6A, MRAS, LLGL2, ACTN2, MAGI1, TJAP1, TJP2, PPP2R2B, MYH2, PRKCZ, ACTN1, SYMPK, PRKCE, AKT3, LLGL1, PRKCH, and CLDN17
Other types of o-glycan biosynthesis	1.63E + 00	7.97E – 03	1.99E – 01	CHST10, CHST10, B4GALT2, FUT4, LFNG, and MFNG
Basal cell carcinoma	1.60E + 00	1.01E – 02	2.15E – 01	WNT11, FZD9, WNT5B, APC2, BMP2, WNT3, WNT7B, WNT6, AXIN2, SHH, FZD2, WNT9B, WNT9A, FZD5, DVL2, HHIP, DVL1, AXIN1, WNT4, WNT5A, and PTCH1
Hypertrophic cardiomyopathy (HCM)	1.56E + 00	1.44E – 02	1.94E – 01	CACNA1C, TNNT2, ITGA11, SGCA, ACTC1, MYH6, RYR2, ITGB4, MYH7, PRKAB2, CACNA1D, TGFB3, DES, CACNB3, PRKAG3, TPM2, CACNA2D1, CACNA2D4, and IL6
Metabolism of xenobiotics by cytochrome p450	1.55E + 00	2.78E – 02	1.92E – 01	ADH4, GSTM5, GSTO2, ALDH3A1, CYP1A1, ADH7, ALDH1A3, ADH1, GSTM2, and MGST2